Sep 28,2022

ABBOTT HOSTS CONFERENCE CALL FOR THIRD-QUARTER EARNINGS

Abbott (NYSE: ABT) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day.

View Analyst & Ambassador Comments
Go to original news
Sep 28,2022

7 innovative digital health offerings to treat diabetes

From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out. Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty.

View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Global Point of Care Glucose Testing Market Report 2022-2026: Focus on Introducing Low-cost Test Strips Driving PoC Glucose Testing Markets

The point of care glucose testing market is poised to grow by $ 972.07 mn during 2022-2026, accelerating at a CAGR of 5.44%. The market is driven by an increase in the number of diabetes cases and rising awareness about diabetes, a growing geriatric population, and increasing unmet medical needs for the diagnosis and management of diabetes.

View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Global Artificial Intelligence in Diabetes Management Market Research Report to 2027 - Featuring Abbott Laboratories, Bigfoot Biomedical, Cardinal Health and Crayon Group Among Others

The Global Artificial Intelligence in Diabetes Management Market size was estimated at USD 452.69 million in 2021, USD 590.45 million in 2022, and is projected to grow at a CAGR 30.60% to reach USD 2,247.24 million by 2027.

View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

Indigo Diabetes N.V., a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Sep 29,2022

Dexcom Schedules Third Quarter 2022 Earnings Release and Conference Call for October 27, 2022 at 4:30 p.m. Eastern Time.

Dexcom today announced that it plans to release its third quarter 2022 financial results after market close on Thursday, October 27, 2022. Management will hold a conference call to review the company's third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

View Analyst & Ambassador Comments
Go to original news
Oct 02,2022

NovioSense Announces Positive Phase 2 Clinical Trial Results and the Commencement of a Second Follow Up Study

NovioSense has demonstrated the measurement of tear glucose in diabetic patients and the correlation to blood glucose with clinically relevant accuracy. The company announced the commencement of a second, 24-patient study, to validate the use of its tear glucose sensor in type 1 diabetic patients.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Oct 02,2022

Contributor: CMS Has Decided to Put Its Muscle Behind Glycemic Management—Why Now?

CMS’ introduction of 3 new electronic clinical quality measures, 2 of which are focused on inpatient glycemic management, signal a strong commitment to shine a light on this often-overlooked area, according to the chief medical officer at Glytec. CMS recently completed its annual update of payment policies and rates for hospitals and long-term care facilities and outlined new rules for the upcoming fiscal year. This included revisions to the Hospital Inpatient Quality-Reporting (IQR) Program, which requires health care facilities to capture and report electronic clinical quality measures (eCQMs), with the goal of “driving quality improvement through measurement and transparency by publicly displaying data to help consumers make more informed decisions about their health care.”

View Analyst & Ambassador Comments
Go to original news
Oct 04,2022 TOP STORY

Positive Results from Pivotal Trial of Better Therapeutics’ Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes Care

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced that the positive 90 day results from its pivotal trial for BT-001, a potentially first-of-its-kind digital therapeutic platform that is designed to use CBT to treat type 2 diabetes (T2D) in patients 18 years and older, have been published in the American Diabetes Association (ADA)-produced, peer reviewed journal Diabetes Care.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Oct 04,2022

Tandem Diabetes Care to Announce Third Quarter 2022 Financial Results on November 2, 2022

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2022 results after the financial markets close on Wednesday, November 2, 2022. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2022 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES